← All trials
NCT05083572
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 10, 2021
- Primary completion
- Nov 30, 2022
- Completion date
- Nov 30, 2022
- First posted
- Oct 19, 2021
- Last posted
- Oct 19, 2021
- Enrollment
- 32
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Changi General HospitalLead sponsor
- Changi General HospitalReponsible party - principal investigator
- Changi General HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.